French Stocks Advance; Eiffage, Manitou, Rexel, Sword, Vetoquinol Increase

France’s CAC 40 Index climbed 56.25, or 1.6 percent, to 3,524.27 at 1:40 p.m. in Paris. The SBF 120 Index also advanced 1.5 percent.

The following shares were among the most active in Paris. Stock symbols are in parentheses.

Accor SA (AC FP) rose 5.15 percent to 24.15 euros, the best performer on the index. Europe’s largest hotel company said yesterday first-half revenue rose 6 percent to 2.85 billion euros ($3.68 billion) as occupancy improved.

Aufeminin.com SA (FEM FP) rose 7.2 percent to 17.1 euros, its highest level since April 2008. The operator of Internet sites targeted at women said yesterday first-half revenue rose to 19.2 million euros from 13.6 million euros a year earlier.

Eiffage SA (FGR FP) climbed 2.1 percent to 38.1 euros, paring yesterday’s 1.8 percent loss. Societe des Autoroutes Paris-Rhin-Rhone SA, the toll-road unit controled by Eiffage, said yesterday that car and truck traffic rose by 4.5 percent in the second quarter.

Hi-Media (HIM FP) plunged 25.1 percent to 3.3 euros, its lowest level in over a year. The direct-marketing company said net income in 2010 would be affected by restructuring, Les Echos reported, without saying where it got the information.

Manitou BF (MTU FP) climbed 4.7 percent to 12.23 euros, extending yesterday’s 1.3 percent gain. The industrial-vehicle maker said second-quarter revenue rose to 225 million euros, from 165.9 million euros a year earlier, and forecast a slowdown in orders in the second half of 2010.

Rexel SA (RXL FP) rose 2.3 percent to 11.5 euros, erasing yesterday’s 2.9 percent loss. The electrical equipment distributor has entered into a six-year, $50 million contract with IT outsourcers CGI Group Inc.

Sword Group (SWP FP) climbed 5.5 percent to 24.9 euros, its biggest advance in over two months. The management consulting firm said second-quarter operating profit rose to 8.45 million euros from 8.3 million euros a year earlier.

Vetoquinol (VETO FP) surged 6.2 percent to 27 euros, its highest level since January 2008. The drug testing company said operating profit for the second-quarter of 2010 rose to 138 million euros, increasing 15 percent from a year earlier.

To contact the reporter on this story: Francesca Angelini in London fangelini1@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.